GSK aims to replace entire HGSI board with its own nominees

If you expected the merger and acquisition standoff between GlaxoSmithKline (NYSE:GSK) and Human Genome Sciences (NASDAQ:HGSI) to come to a resolution next week, think again. GSK plans to replace HGS&…
Read the full story: MedCity News